---
schema_version: "secwatch.filing_event.v1"
accession: "0001321732-26-000006"
form_type: "8-K"
ticker: "PEN"
cik: "0001321732"
company_name: "Penumbra Inc"
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:09:21.973585+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Penumbra Q4 revenue $385.4M (+22.1%); operating income $59.2M; FY25 rev $1.4B (+17.5%)

## Summary
- Revenue $385.4M for Q4, up 22.1% YoY (20.9% constant currency). US Thrombectomy $203.1M (+12.4%).
- Gross margin 68.0% vs 66.8% a year ago; operating margin 15.4%.
- Net income $47.3M; adjusted EBITDA $79.1M (20.5% margin).
- Full year revenue $1,403.7M, up 17.5%; net income $177.7M; adjusted EBITDA $266.8M.
- Embolization & access revenue grew 37.0% in Q4; international revenue up 27.7% (21.9% constant currency).

## SEC filing metadata
- accession: 0001321732-26-000006
- form_type: 8-K
- ticker: PEN
- cik: 0001321732
- company_name: Penumbra Inc
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321732/000132173226000006/0001321732-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321732/000132173226000006/pen-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001321732-26-000006
- JSON: https://secwatch.observer/filing/0001321732-26-000006.json
- Plain text: https://secwatch.observer/filing/0001321732-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.